Xinda Securities·2025-12-11 07:59Investment Rating - The report assigns a "Buy" investment rating to the company [2][6]. Core Insights - The company has completed adjustments in its governance structure and management team, marking a new development phase and focusing on high-quality growth [5][14]. - The company reported a significant increase in net profit for Q3 2025, with a year-on-year growth of approximately 29% [31]. - The dividend payout ratio is set to increase to 46% in 2024, with corresponding increases in dividend yields for both A-shares and H-shares [5][35]. Summary by Sections Governance Changes and Strategic Focus - The company has completed the adjustment of its senior management team, with new leadership expected to enhance operational quality [16][30]. - The new governance structure emphasizes internationalization, digital transformation, and innovation in research and development [30]. - The company is advancing its strategic planning for the "15th Five-Year Plan" while ensuring the completion of the "14th Five-Year Plan" [37][38]. Business Performance - The commercial segment remains a cornerstone of revenue, with a compound annual growth rate (CAGR) of approximately 6% from 2020 to 2024 [15][39]. - The traditional Chinese medicine segment is under short-term pressure, with a decline in revenue due to inventory adjustments and increased competition [15][41]. - The health segment is experiencing growth, with a revenue increase of over 7% in the first half of 2025 [15][45]. Financial Projections - Revenue projections for 2025-2027 are estimated at 790.01 billion, 840.61 billion, and 894.5 billion respectively, with corresponding net profits of 37.35 billion, 39.63 billion, and 44.27 billion [6][7]. - The company anticipates a net profit growth of approximately 31.7% in 2025, followed by more moderate growth in subsequent years [6][7]. Dividend Policy - The company plans to increase its dividend payout ratio to 46% in 2024, significantly higher than the 30% range maintained from 2019 to 2023 [5][35]. - The expected dividend yield for A-shares is approximately 2.81%, while H-shares are projected to yield around 4.83% [5][35].